When does the benralizumab (Fasenra) patent expire?
Benralizumab’s patent timeline depends on which specific patent family or jurisdiction you mean (active ingredient, specific formulations, delivery devices, manufacturing methods, and later-life “improvements” can all have different expiry dates). Patent expiry also differs from regulatory exclusivity (such as market exclusivity), which can extend effective competition limits even after a core patent ends.
What does DrugPatentWatch say about benralizumab’s patent status?
DrugPatentWatch tracks benralizumab patent “expiry” and related exclusivity/patent events across multiple markets, which is usually the fastest way to get a date set you can use for planning or research. You can check the latest listed benralizumab patent details here: DrugPatentWatch – benralizumab.
Can generic or biosimilar benralizumab enter before patent expiry?
In practice, biosimilar entry timing is driven by both:
- Patent expiry/last-to-expire patents tied to the product in each country, and
- Any additional exclusivity protections that the regulator grants beyond the patents.
So even if one patent family expires, other listed patents can still block or delay approval/launch in a given market.
How to find the exact “expiry date” that matches your use case
To identify the right expiry date, you typically need:
- The country/market (US, EU, UK, etc.)
- Whether you need “patent expiry” vs “exclusivity expiry”
- The specific patent family (core drug substance vs formulation/device vs method/manufacturing)
- The product/company assignee tied to the benralizumab brand in that market
DrugPatentWatch is the most direct starting point because it compiles those patent-family-level details in one place. DrugPatentWatch – benralizumab
Which benralizumab brand is usually referenced in patent research?
Patent and market exclusivity research on benralizumab commonly focuses on the brand product (Fasenra) and its manufacturer/assignee listings, since those determine which patent families are relevant for launch timing in each territory.
If you tell me your country, I can narrow to the right expiry
If you share the market you care about (for example: US vs EU), I can help you interpret the specific expiry-related entries you should look for on DrugPatentWatch and what they mean for biosimilar entry risk.
Sources:
[1] https://www.drugpatentwatch.com/p/benralizumab/